Superficial venous thrombosis (SVT) is the complications of varicose great saphenous veins (VGSVs), but its pathogenesis remains unclear. This study was designed to measure the changes in expression of matrix metalloproteinases (MMPs) and the tissue inhibitor of metalloproteinases (TIMPs) from SVT, VGSVs, and great saphenous veins (GSVs).
Methods
In the venous walls of the three groups, the expression of MMP-2, MMP-9, TIMP-1, and TIMP-2 proteins, protein-positive expression ratios, mRNA expression, and protein expression were determined by immunohistochemistry, polymerase chain reaction, and western blot.
Results
The MMP-2, MMP-9, TIMP-1, and TIMP-2 protein-positive expression ratios, mRNA and protein expression in the SVT group were significantly higher than those in the VGSV and the GSV groups. The corresponding expression in the VGSV group were significantly higher than those in the GSV group.
Conclusion
Disequilibrium of MMPs and TIMPs in SVT wall occurs due to underlying high hydrostatic pressure and inflammation. These results suggested that MMPs and TIMPs participate in the process of venous wall remodeling.
Beebe-DimmerJLPfeiferJREngleJS, et al.
The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol2005;
15: 175–184.
2.
RaffettoJDQiaoXBeauregardKG, et al.
Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg2010;
51: 972–981.
3.
TakaseSBerganJJSchmid-SchonbeinG.Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg2000;
14: 427–435.
4.
SayerGLSmithPDC.Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg2004;
28: 479–483. AQ1
5.
BerganJJSchmid-SchonbeinGWSmithPDC, et al.
Chronic venous disease. N Engl J Med2006;
355: 488–498.
Di NisioMWichersIMMiddeldorpS.Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev2018;
2: CD004982.
8.
RaffettoJDRossRLKhalilRA.Matrix metalloproteinase 2–induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg2007;
45: 373–380.
9.
KucukguvenAKhalilRA.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets2013;
14: 287–324.
10.
CuiNHuMKhalilRA.Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci2017;
147: 1–73.
ChenYPengWRaffettoJD, et al.
Matrix metalloproteinases in remodeling of lower extremity veins and chronic venous disease. Prog Mol Biol Transl Sci2017;
147: 267–299.
13.
MacCollEKhalilRA.Matrix metalloproteinases as regulators of vein structure and function: implications in chronic venous disease. J Pharmacol Exp Ther2015;
355: 410–428.
14.
AsanumaKMagidRJohnsonC, et al.
Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol2003;
284: H1778–1784.
15.
RaffettoJDQiaoXKoledovaVV, et al.
Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: potential implications in varicose veins. J Vasc Surg2008;
48: 447–456.
16.
DeatrickKBEliasonJLLynchEM, et al.
Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg2005;
42: 140–148.
17.
ZhangYBLiWYaoLQ, et al.
Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis. Chin J Traumatol2010;
13: 188–192.
18.
HuXXHuFXXuYB, et al.
Disequilibrium in MMPs and the tissue inhibitor of metalloproteinases in different segments of the varicose great saphenous vein wall. Int Angiol2019;
38: 185–193.
19.
Badier-CommanderCVerbeurenTLebardC, et al.
Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol2000;
192: 105–112.
20.
NaikBKumarMKhannaAK, et al.
Clinico-histopathological study of varicose vein and role of matrix metalloproteinases-1, matrix metalloproteinases-9 and tissue inhibitor of matrix metalloproteinase-1 in varicose vein formation. Indian J Pathol Microbiol2016;
59: 25–30.
21.
JianFGChuHBLiuG, et al.
Morphological characteristics of the walls of thrombophlebitic saphenous vein. Phlebology2014;
29: 164–170.
22.
ChuHBYanFZhaoJH, et al.
Assessment of the infiltration of inflammatory cells in the walls of thrombotic varicose veins. Angiology2013;
64: 69–72.
23.
RaffettoJDKhalilRA.Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol2008;
75: 346–359.
24.
Sansilvestri-MorelPFiorettiFRupinA, et al.
Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes?Clin Sci (Lond)2007;
112: 229–239.
25.
GomezIBenyahiaCLouedecL, et al.
Decreased PGE 2 content reduces MMP-1 activity and consequently increases collagen density in human varicose vein. PLoS One2014;
9: e88021.
26.
SerralheiroPCairrãoEMaiaCJ, et al.
Effect of TGF-beta1 on MMP/TIMP and TGF-beta1 receptors in great saphenous veins and its significance on chronic venous insufficiency. Phlebology2017;
32: 334–341.
27.
SerraRGrandeRBuffoneG, et al.
Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines. Int Wound J2016;
13: 53–58.
28.
SerraRGallelliLButricoL, et al.
From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases. Int Wound J2017;
14: 233–240.
29.
NomuraSYoshimuraKAkiyamaN, et al.
HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res2005;
37: 370–378.
30.
KimHKSongKSParkYS, et al.
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer2003;
39: 184–191.
31.
MalikJStulcTCeskaR.Matrix metalloproteinases in isolated hypercholesterolemia. Int Angiol2005;
24: 300–303.
32.
GreselePFalcinellESebastianoM, et al.
Matrix metalloproteinases and platelet function. Prog Mol Biol Transl Sci2017;
147: 133–165.
33.
LoodCAmistenSGullstrandB, et al.
Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood2010;
116: 1951–1957.
34.
Rodríguez-PeraltoJLCarrilloRRosalesB, et al.
Superficial thrombophlebitis. Semin Cutan Med Surg2007;
26: 71–76.
35.
XuYBBeiYYLiY, et al.
Phenotypic and functional transformation in smooth muscle cells derived from varicose veins. J Vasc Surg Venous Lymphat Disord2017;
5: 723–733.
36.
NaikBKumarMKhannaAK, et al.
Clinico-histopathological study of varicose vein and role of matrix metalloproteinases-1, matrix metalloproteinases-9 and tissue inhibitor of matrix metalloproteinase-1 in varicose vein formation. Indian J Pathol Microbiol2016;
59: 2–30.
37.
GillespieDLPatelAFiletaB, et al.
Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res2002;
106: 233–238.
38.
KowalewskiRSobolewskiKWolanskaM, et al.
Matrix metalloproteinases in the vein wall. Int Angiol2004;
23: 164–169.
39.
ReddyVSPrabhuSDMummidiS, et al.
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol2010;
299: H1242–1254.
